Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview.

ABSTRACT:

Background

Therapeutic drug monitoring involves therapeutic modifications based on the measurement of drug levels and antidrug antibodies. The viability of therapeutic drug monitoring in vedolizumab-treated patients with inflammatory bowel disease remains questioned.

Main body

Accumulating evidence from clinical trials and real-world data suggests that an exposure-efficacy relationship may exist for vedolizumab in inflammatory bowel disease, but results are not as straightforward as they are for anti-tumour necrosis factor-α therapy. Robust target vedolizumab trough levels are currently missing, since available data are heterogenous and prospective, interventional pharmacokinetic-pharmacodynamic studies are lacking. The positioning of vedolizumab drug monitoring in therapeut

SUBMITTER: Pouillon L 

PROVIDER: S-EPMC6505179 | biostudies-literature | 2019 May

REPOSITORIES: biostudies-literature